We have located links that may give you full text access.
An optimization algorithm for designing phase I cancer clinical trials.
Contemporary Clinical Trials 2008 March
Numerous phase I dose finding clinical trials are conducted everyday to find the "maximum tolerated dose" (MTD) of a cancer treatment. Although various Bayesian designs for Phase I clinical trials have been proposed in the literature, the traditional 3+3 design is still widely used because of its algorithm-based simplicity in logistics for the clinical investigators to carry out in comparison with model-based Bayesian methods. In this paper, we propose an optimization algorithm for designing phase I cancer clinical trials. This algorithm does not need assumptions on the true dose-response relationship but can readily incorporate available prior information about the true response probabilities. It searches for an approximately optimal design within a design space, in which the 3+3 design is included as a special case. Simulation studies show that the design recommended by this algorithm significantly outperforms the 3+3 design.
Full text links
Related Resources
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app
All material on this website is protected by copyright, Copyright © 1994-2024 by WebMD LLC.
This website also contains material copyrighted by 3rd parties.
By using this service, you agree to our terms of use and privacy policy.
Your Privacy Choices
You can now claim free CME credits for this literature searchClaim now
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app